Pathstone Holdings LLC Has $34.56 Million Position in Novo Nordisk A/S (NYSE:NVO)

Pathstone Holdings LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.3% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 290,229 shares of the company’s stock after purchasing an additional 734 shares during the period. Pathstone Holdings LLC’s holdings in Novo Nordisk A/S were worth $34,558,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Natixis Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after buying an additional 80,070 shares during the last quarter. Zions Bancorporation N.A. boosted its holdings in Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after purchasing an additional 37,346 shares during the last quarter. Private Wealth Partners LLC increased its holdings in shares of Novo Nordisk A/S by 155.1% during the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock worth $3,953,000 after purchasing an additional 20,188 shares during the period. Finally, Buckingham Capital Management Inc. acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at about $3,874,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.9 %

Shares of NVO opened at $99.82 on Tuesday. The stock has a 50 day simple moving average of $117.94 and a 200-day simple moving average of $129.42. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market cap of $447.95 billion, a PE ratio of 32.30, a PEG ratio of 1.31 and a beta of 0.42. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on NVO. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.